If Semaglutide Can Do This, The World Changes

Original posted at obesity.news/ on Nov 22, 2025

There is something coming in the next few days in the GLP-1 world that feels bigger than anything we have covered on On The Pen. Bigger than the supply chain fights. Bigger than the PBM battles. Bigger than the access wars. Something that reaches into the softest parts of the human experience. Memory. Identity. The fear of losing ourselves before losing our lives.

In the next couple of weeks, the results from the Evoke and Evoke+ trials are expected. These are the massive global studies testing oral semaglutide in early Alzheimer’s. For most people, these trials have been running quietly in the background while we have all been focused on weight and diabetes. But deep in the science, there has been so much more churning.

Could semaglutide slow the progression of early Alzheimer’s?

If the answer is yes, this would be one of the most important medical moments of our lifetime.

Why test the oral form instead of the injectables we already know

People ask this constantly. If Wegovy and Ozempic use the same pathway, why not test those.

Why use something different that could potentially be more powerful?

There are three reasons.

The first is practicality. Introducing weekly injections into an already vulnerable population can disrupt routines that families rely on. Pills fit more gently into the daily rhythm of someone with cognitive changes. Caregivers can help without confusion or fear. It helps with adherence, and these trials rise and fall on consistency.

The second is likely about weight management. Oral semaglutide in lower doses tends to lead to less weight loss. In a population that struggles with routine changes and presents nutritional challenges, I think that’s kind of the point. Oral semaglutide, at the doses used in these trials, lightly engages the GLP-1 pathway without the dramatic weight loss we see at higher injectable doses. That makes it the safer, cleaner option for studying brain protection. It supports the person without destabilizing the body. And it lets researchers see what the drug is doing in the brain without the confounding effects of major changes on the scale.

The third reason might be the most important. If an oral GLP-1 shows protection in this population, it becomes scalable. It becomes accessible. It becomes something that can be introduced early in the disease without adding complexity.

A simple pill with the power to slow decline. That is the dream.

Why would a GLP 1 medication help the brain?

Emerging science keeps showing the same pattern. Semaglutide is doing far more than turning down appetite. It is calming inflammation. It is improving vascular function. It reducing insulin resistance. It is restoring metabolic stability in ways that ripple through every single organ system.

And the brain is an organ.

We see early signals everywhere. Lower inflammation. Better blood flow. Improved cellular housekeeping. Reduced oxidative stress. None of these outcomes require weight loss. They happen whether the number on the scale moves or not. This is why researchers keep circling back to the same idea.

The benefits of semaglutide may not be primarily about weight. Weight loss may just be the visible symptom of much deeper healing.

Subscribe

What the trials are actually trying to show

At the center of the Evoke trials is one question. Can this drug slow the quiet unraveling of early Alzheimer’s?

The primary measure is the CDR Sum of Boxes, a tool that tracks the parts of life that matter most. Memory. Orientation. Judgment. Hobbies. Personal care. Social life. The pieces that fade as the disease progresses.

If semaglutide slows that decline over two years, even by a small margin, it is historic. A drug that already changes bodies could also be protecting brains.

That is not weight loss. That is not cosmetic. That is humanity. And that’s what we always say these drugs do here at OTP, they give people their lives back.

Why this moment matters so much for anyone who has watched someone fade

This is where the science becomes so personal to me.

My grandma is currently living with Alzheimer’s. Her husband, my grandpa, died from it. I have watched what this disease steals long before it takes a life. The long early grief. The missing moments. The quiet confusion. The way a familiar voice begins to sound like someone else. There is a weight to those moments that never leaves you.

I have sat beside my grandma and watched her reach for memories that used to come so freely. I have watched her try to stitch together pieces of her life while the thread slipped through her fingers. I have seen that flicker of uncertainty in her eyes and I have seen the courage she still carries even when the world inside her head shifts.

I have watched my grandpa slip away a little at a time. The confusion. The flashes of recognition. The softening of his voice when he knew he was losing his place in the world. These things change you. They sit inside you. They make you hope for things you never thought you would hope for.

So when I talk about these trials, I am speaking from a place of longing. I am speaking from the part of me that wishes they could have stayed themselves longer. One more good day. One more real conversation. One more moment where the light did not flicker.

That is why this matters. That is why this entire field is watching. That is why our community deserves to know what could be coming. Because if semaglutide protects even a little, families get more time. More presence. More of the person they love.

And that is everything.

Why this moment matters for the GLP 1 community

We know what it feels like to be misunderstood. To be brushed off as vain or lazy or looking for shortcuts. But if semaglutide shows protection for the brain, the entire conversation changes.

These medications operate through every corner of the body. They do not just silence hunger. They quiet storms that diet culture never acknowledged. They heal in ways most people never realized.

And if the brain is one of those places, this becomes something far bigger than obesity medicine.

This becomes a medical turning point.

The next two weeks could shift the world

We still do not know what the results will show. We still do not know how strong the effect will be. But for the first time in a long time, there is a real chance. A chance that something millions of people already take could protect the mind. Slow the fade. Hold the pieces together a little longer.

If that is even possible, it is worth preparing your heart for.

And when the data arrives, you will hear it here first. With honesty, with clarity, and with the voice of someone who carries this topic deeply.

Have a great weekend. Jen, the oldest boys and I will be heading down to the Iowa VS Michigan State game here in a bit, follow our day here in my Instagram stories if you’d like!

This article is reader-supported on Substack.

To receive new posts and support my work,

consider becoming a free or paid subscriber.

Subscribe